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Endothelial Function Predicts Progression of Carotid
Intima-Media Thickness
Julian P.J. Halcox, MA, MD, FRCP; Ann E. Donald, AVS; Elizabeth Ellins, MA;
Daniel R. Witte, PhD; Martin J. Shipley, MSc; Eric J. Brunner, PhD;
Michael G. Marmot, PhD, FRCP; John E. Deanfield, MB, FRCP
Background—Endothelial dysfunction develops early and has been shown to predict the development of clinical
complications of atherosclerosis. However, the relationship between early endothelial dysfunction and the progression
of arterial disease in the general population is unknown. We investigated endothelial dysfunction, risk factors, and
progression of carotid intima-media thickness (cIMT) in late-middle-aged individuals at low to intermediate cardiovascular
risk in a prospective study between 1997 and 2005.
Methods and Results—Brachial artery flow-mediated dilatation and cIMT were measured in 213 nonsmoking British civil
servants recruited from a prospective cohort (Whitehall II study). Participants (age, 45 to 66 years) were free of clinical
cardiovascular disease and diabetes mellitus. Risk factors and Framingham Risk Score were determined at baseline.
cIMT was repeated 6.20.4 years later. At baseline, age, blood pressure, low-density lipoprotein cholesterol, and
Framingham Risk Score correlated with cIMT. However, only flow-mediated dilatation, not risk factors or Framingham
Risk Score, was associated with average annual progression of cIMT. This relationship remained significant after
adjustment for risk factors whether entered as separate variables or as Framingham Risk Score. Further adjustment for
waist circumference, triglycerides, and employment grade had no significant effect.
Conclusions—Systemic endothelial function was associated with progression of preclinical carotid arterial disease over a 6-year
period and was more closely related to cIMT changes than conventional risk factors. Thus, the relationship between
endothelial dysfunction and adverse outcome is likely to be due not only to destabilization of established disease in high-risk
populations but also to its impact on the evolution of the atherosclerotic substrate. Flow-mediated dilatation testing provides
an integrated vascular measure that may aid the prediction of structural disease evolution and represents a potential short- to
intermediate-term outcome measure for evaluation of preventive treatment strategies. (Circulation. 2009;119:1005-1012.)
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Atherosclerosis is a multifactorial disease that begins inchildhood and typically evolves over a long preclinical
phase until it results in morbidity and mortality, usually from
middle age onward.1 Several recognized risk factors, includ-
ing low-density lipoprotein (LDL) cholesterol, diabetes mel-
litus, hypertension, and smoking, have been shown to have a
causal role.2–4 They are predictive of cardiovascular outcome
and are amenable to safe and effective interventions that im-
prove prognosis.5–9 However, atherosclerosis also develops in a
significant number of individuals with relatively modest risk
factor profiles,10 highlighting the need for measures that improve
the prediction of disease progression and risk stratification.
Editorial p 919
Clinical Perspective p 1012
The vascular endothelium has a central role in the main-
tenance of vascular health.11,12 By recognizing and respond-
ing to local physical and chemical signals, endothelial cells
are able to influence vasomotor, thrombotic, inflammatory,
and cellular proliferation pathways, thus affecting both the
short- and long-term biology of the vessel wall. Endothelial
dysfunction (ED) has been shown to predict clinical outcome
in high-risk cohorts, including the elderly,13 patients with
peripheral vascular disease, hypertensive patients, and those
undergoing cardiac catheterization.14–17 This may be due to
enhancement of local inflammation and a prothrombotic
tendency in the arterial wall, which may increase risk by
promoting plaque instability and arterial thrombosis.
In addition, we and others have shown that ED may
develop decades before clinical presentation in patients with
conventional risk factors (RFs) such as hypercholesterolemia,
diabetes, and smoking and novel RFs such as obesity,
infection, and inflammation.18–23 The development of arterial
ED with reduced nitric oxide bioavailability may alter unfa-
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vorably the balance between vascular injury and repair and
thus promote conditions favoring lesion development. How-
ever, the impact of ED on the progression of structural arterial
disease in the preclinical population has not been evaluated
prospectively.
Endothelial function and structural arterial changes can be
measured noninvasively with high-resolution ultrasound to
measure brachial artery flow-mediated dilatation (FMD) and
carotid artery intima-media thickness (cIMT), respectively.24
We have used these techniques in a well-characterized
prospective cohort of middle-aged British civil servants (the
Whitehall II study) to evaluate the role of the endothelium in
the evolution of structural arterial disease.
Methods
Study Population
The Whitehall II study population consists of 10 308 nonindustrial
civil servants who have been followed up approximately every 2.5
years since entry between 1985 and 1988.25 We recruited 282
participants into a vascular substudy investigating the relationship
between metabolic RFs and preclinical vascular phenotype. Partici-
pants were selected at the phase 5 (1997 to 1999) evaluation of the
Whitehall II study from among nonsmokers who had no history of
diabetes mellitus or clinical cardiovascular disease identified at this
phase. These participants underwent assessment of cardiovascular
disease RFs (blood pressure, fasting glucose, total cholesterol, LDL
and high-density lipoprotein [HDL] cholesterol, triglycerides, and
waist circumference), cardiovascular disease status, and measures of
body habitus FMD and cIMT at baseline. Reassessment of cIMT was
undertaken 6.20.4 years later at phase 7 (2003 to 2005). We
excluded 7 individuals in whom it was impossible to acquire IMT
data of adequate quality for analysis at baseline and 62 who did not
return for a follow-up assessment of IMT, leaving 213 participants
for analysis.
RF Measurement
Blood pressure was measured twice in subjects in the sitting position
after 5 minutes of rest with the Hawksley random-zero sphygmoma-
nometer. Waist circumference (smallest circumference at or below
the costal margin) was measured with participants unclothed in the
standing position with a fiberglass tape measure at 600-g tension.
Fasting plasma glucose, total cholesterol, HDL cholesterol, and
triglyceride levels were determined as previously reported.26 LDL
was calculated from the Friedewald formula.27 For each participant,
the predicted 10-year risk (Framingham Risk Score [FRS]) of a
cardiovascular event was calculated from age, sex, systolic blood
pressure, and total and HDL cholesterol levels.4
Vascular Measurements
All studies were performed in a temperature-controlled (22°C to
26°C) vascular laboratory by 2 trained operators after a 10-minute
rest. All participants abstained from food and caffeinated drinks for
4 hours, and those treated with antihypertensive therapy refrained
from taking their medication for 48 hours.
Brachial Artery Vasomotor Function
Brachial artery vasomotor function was assessed with high-
resolution ultrasound as previously reported,28 with arterial diameter
analysis done with an automated edge detection system (Brachial
Tools, Iowa City, Iowa). FMD was expressed as a percentage from
baseline. The overall coefficient of variation for repeated measures
of FMD in our laboratory is 11%.
Carotid Artery IMT
Longitudinal images of the common carotid artery 1 cm proximal to
the bifurcation in which the far wall intima-media interface (M-line)
was clearly defined were magnified and recorded on videotape for
later analysis. The distance between the leading edge of the intima
and the media-adventitia interface was measured with ultrasonic
calipers. Three measurements were taken in both the right and left
common carotid arteries, and a mean IMT was calculated as
previously described.29,30 cIMT was assessed on 2 occasions: a
baseline analysis at phase 5 (1997 to 1999) and a follow-up
evaluation at phase 7 (2003 to 2005). The annual rate of progression
of cIMT (cIMT per year) was determined by subtracting the cIMT
at phase 5 from the cIMT at phase 7 and then dividing this value
(expressed in micrometers) by the time interval in years between
the phase 5 and 7 evaluations for each participant. The overall
coefficient of variation for repeated measures of cIMT in our
laboratory is 5%.
Statistical Analysis
The analysis data set was almost complete, with only blood pressure
(1 missing value), HDL and LDL (27 missing), and waist measure-
ments (44 missing) having any missing values. These missing values
were replaced with RF data from phase 3 (1991 to 1993) to provide
a complete data set. The distributions of cIMT and the annual rate of
cIMT progression were both normally distributed. Contemporaneous
data were used to evaluate cross-sectional relationships between RFs
and measures of vascular function and structure at baseline. RFs and
FMD at phase 5 also were used to explore relationships with cIMT
per year. These associations were initially described by tabulating
mean RFs by quartiles of cIMT and progression of cIMT. Univariate
between-group comparisons were made with t tests or Mann-
Whitney tests for nonnormally distributed data. Bivariate correla-
tions between parameters were assessed with the Pearson or Spear-
man correlation coefficient for normally or nonnormally distributed
variables, respectively.
Linear regression analysis was used to assess the relationships
between baseline cIMT or annual rate of progression of cIMT and
RFs, including FMD. These relationships were fitted by use of
least-squares regression with cIMT or annual rate of progression as
the dependent variable. Additional analyses confirmed that no
evidence existed (all P0.70) for any departures from the assump-
tion of linearity. The associations of cIMT and progression of cIMT
with the RFs were summarized through the use of the regression
coefficient and  coefficient showing the change (on the unstand-
ardized and standardized scales) in the outcome associated with a
unit change in the RFs. Because no evidence was found that the
relationships differed by sex, men and women were pooled in the
analyses when possible. Each RF relationship, adjusted for age and
sex, was first assessed separately (Tables 1 and 2). When adjusting
for age and sex, we allowed the relationships of each RF with age to
differ between the sexes. The analyses for the effects of waist
circumference and HDL were done in men and women separately
because the mean levels of these RFs showed large sex differences.
The relationship between the annual rate of progression of cIMT and
FMD was examined further with multiple linear regression (Table 3)
to assess the effect of additional adjustment for the Framingham
cardiovascular disease RFs (age, sex, blood pressure, smoking,
diabetes mellitus, and total and HDL cholesterol) entered into the
model as both individual variables and the FRS. Further adjustments
to the model were made for waist circumference (as a measure of
abdominal obesity) and triglyceride levels, which are widely recog-
nized as the principal emerging clinical markers of cardiometabolic
risk not accounted for by the Framingham variables.
The value of using FMD to predict an adverse progression of
cIMT, defined as having an annual rate of cIMT progression in the
highest 25% of the distribution, was assessed with receiver-operating
characteristic curves. The sensitivity and specificity of using a cut
point of FMD to predict the upper quartile of cIMT progression were
calculated. They were used to determine the cut point for FMD that
gave the best (defined as the point at which the sum of sensitivity
plus specificity was greatest) prediction of cIMT progression. Anal-
yses were performed with SPSS version 14.0 (SPSS Inc, Chicago,
Ill) and SAS version 8.1 (SAS Institute, Inc, Cary, NC).
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integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Participants
Two participants were receiving treatment with statins at
phase 5, and 27 individuals were being treated with antihy-
pertensive agents. These individuals were included in the
primary analysis (Table 1).
Of the 62 participants who attended at baseline but did not
attend for follow-up vascular assessment at phase 7, 35
attended for general assessment as part of the main Whitehall
II study but chose not to accept the written and follow-up
telephone invitation to reattend for vascular assessment, 5
formally withdrew from the study, 2 died, 2 were lost to
follow-up, 9 requested a home visit for their general phase 7
assessment and were unable to attend the vascular laboratory,
and 9 chose not to attend for any follow-up assessment at
phase 7. Baseline diastolic blood pressure was higher in those
who did not return for follow-up vascular assessment
(79.110.1 versus 75.49.5 mm Hg; P0.009), but all other
RFs assessed at baseline, including FRS and FMD, were
similar to the RFS of those who reattended at phase 7.
Vascular Structure and Function
Baseline Vascular Measures
Men had slightly lower FMD (4.952.92% versus
5.583.03%; P0.18) and higher cIMT (707 versus 674 m;
P0.13) than women at their baseline assessment.
Relationships Between RFs and Baseline
Vascular Measures
Age (r0.23, P0.001) was inversely correlated with
FMD. Waist circumference (P0.02) and both systolic and
diastolic blood pressures (both P0.001) also were in-
versely associated with FMD after adjustment for age and
sex. Lipid parameters and fasting glucose were not asso-
ciated with FMD.
Age, systolic blood pressure, total cholesterol, and LDL
cholesterol were correlated with baseline cIMT. Only the
relationships between cIMT and age and LDL cholesterol
remained after adjustment for age and sex (Table 1). FMD,
waist circumference, and other associated metabolic RFs,
including HDL, triglycerides, and fasting glucose levels were
not correlated with cIMT. FRS was correlated strongly with
baseline cIMT (r0.24, P0.001) and inversely with FMD
(r0.27, P0.001).
Annual Rate of Progression of cIMT
The mean annual rate of progression of cIMT (the Figure)
was 0.0120.028 mm/y and was similar in men and women.
It was correlated with age (r0.16, P0.02), FMD
(r0.19, P0.006), and blood pressure (systolic blood
pressure: r0.13, P0.07: diastolic blood pressure: r0.15,
P0.03). After adjustment for age and sex, FMD and
diastolic blood pressure were the only parameters of those
assessed at baseline, including FRS, that remained associated
with progression of cIMT (Table 2).
The relationship between FMD and progression of cIMT
remained after adjustment for FRS variables, whether entered
Table 1. Total Sample Characteristics and Association of cIMT at Baseline (Phase 5: 1997 to 1999) With RFs
Total Sample
(n213)
cIMT Quartiles Regressions of cIMT vs RFs
Q1 (Lowest)
(n50) Q2 (n61) Q3 (n47)
Q4 (Highest)
(n55)
Regression
Coefficient*
(SE), m P † (SE), m
Age, ‡ y 55.95.5 54.1 (0.76) 55.8 (0.69) 56.2 (0.78) 57.4 (0.73) 5 (2) 0.01 26 (11)
Female gender, ‡ % 39.4 46.0 41.0 36.2 34.6 26 (22) 0.24 26 (22)
Waist, § cm
Men 87.710.1 84.4 (2.2) 88.7 (1.9) 88.5 (2.0) 87.5 (1.9) 0.6 (1.5) 0.69 7 (17)
Women 80.813.3 81.5 (2.4) 78.9 (2.2) 81.2 (2.7) 84.0 (2.6) 0.9 (1.1) 0.45 10 (13)
SBP, § mm Hg 11915.6 117 (2.2) 117 (1.9) 119 (2.2) 122 (2.1) 1.1 (0.7) 0.13 16 (11)
DBP, § mm Hg 75.59.5 74.4 (1.4) 74.7 (1.2) 76.4 (1.4) 76.7 (1.3) 0.8 (1.1) 0.45 8 (11)
Cholesterol, § mmol/L 5.760.97 5.62 (0.14) 5.80 (0.12) 5.81 (0.14) 5.81 (0.13) 16.3 (11.1) 0.14 16 (11)
HDL, § mmol/L
Men 1.360.32 1.47 (0.07) 1.27 (0.06) 1.38 (0.06) 1.36 (0.06) 15 (46) 0.74 6 (17)
Women 1.610.41 1.70 (0.08) 1.66 (0.07) 1.49 (0.09) 1.55 (0.08) 4 (36) 0.92 1 (14)
Triglycerides, § mmol/L 1.190.71 1.04 (0.10) 1.29 (0.09) 1.26 (0.10) 1.16 (0.10) 0.9 (15.0) 0.95 1 (11)
LDL, § mmol/L 3.830.94 3.64 (0.13) 3.85 (0.12) 3.86 (0.14) 3.93 (0.13) 21 (11) 0.06 20 (11)
Fasting glucose, § mmol/L 5.301.18 5.34 (0.17) 5.23 (0.15) 5.07 (0.17) 5.54 (0.16) 7.5 (9.0) 0.40 9 (11)
FMD, § mm 0.230.12 0.20 (0.02) 0.24 (0.02) 0.24 (0.02) 0.22 (0.02) 93 (88) 0.29 11 (11)
FMD, § % 5.172.97 4.33 (0.41) 5.49 (0.37) 5.70 (0.42) 5.13 (0.39) 6.0 (3.4) 0.10 18 (11)
Q indicates quartile; SBP, systolic blood pressure; and DBP, diastolic blood pressure. Values are meanSD or median (SE) as appropriate.
*Regression coefficient shows the change in cIMT associated with a unit change in the RF.
† Coefficient shows the change in cIMT associated with a 1-SD change in the RF (regression coefficient shown for gender).
‡Regression and  coefficients for age and gender are mutually adjusted. Coefficients for gender are for women vs men.
§Adjusted for age and gender.
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into the model as individual variables or as the composite
FRS (Table 3). Further adjustment for waist circumference
and triglycerides, the other modifiable markers of cardiomet-
abolic risk, in addition to FRS variables, did not affect the
relationship between FMD and progression of cIMT
(5.0, P0.01). Employment grade was not significantly
associated with FMD, cIMT, or progression of IMT, and
adjustment for grade had very little effect on the results.
Reactive hyperemia (the flow stimulus for FMD) was not
associated with cIMT progression (P0.14), and adjustment
for reactive hyperemia did not alter the strength or signifi-
cance of the relationship between FMD and cIMT progres-
sion (4.8 m/y; P0.02). Brachial artery diameter
(P0.02), but not carotid artery diameter (P0.78), was
associated with cIMT progression.
The association between FMD and cIMT progression was
similar if the 27 patients who were treated with antihyperten-
sive drugs and the 2 patients receiving statin therapy were
omitted from the analysis (data not shown).
Receiver-operating characteristic analysis exploring the
ability of baseline data to predict a rate of cIMT progression
in the highest quartile of the distribution, demonstrated areas
under the curve of 0.539 for FRS and 0.632 for FMD.
Combining both FMD and FRS data did not provide incre-
mental predictive power over FMD alone (area under the
curve0.633). A value of FMD 4.10% provided the best
discriminatory ability, at which point sensitivity was 58%,
specificity was 65%, positive predictive value was 36%, and
negative predictive value was 83% for the prediction of those
likely to have a rate of cIMT progression in the top quartile
of the distribution.
Discussion
Endothelial function is known to predict clinical events in
high-risk subjects. We now demonstrate for the first time that
Table 2. Association of cIMT per Year Between Phases 5 and 7 With WFs
cIMT per Year Quartiles Regressions of cIMT per Year vs RFs
Q1 (Lowest) (n52)* Q2 (n53) Q3 (n55) Q4 (Highest) (n53)
Regression
Coefficient,† m P ,‡ m
Age,§ y 54.9 (0.75) 55.7 55.6 57.5 0.8 (0.3) 0.02 4.4 (1.9)
Gender,§ (% women) 38.5 37.7 49.1 32.1 0.6 (3.9) 0.88 0.6 (3.9)
Employment grade, % low 19.4 16.6 23.9 12.3 3.4 (5.4) 0.53 3.4 (5.4)
Waist, cm
Men 85.6 (2.0) 90.1 91.2 83.3 0.03 (0.26) 0.90 0.4 (3.1)
Women 83.0 (2.5) 82.4 80.2 79.8 0.20 (0.21) 0.34 2.4 (2.5)
SBP, mm Hg 118 (2.1) 116 121 120 0.19 (0.12) 0.12 3.0 (1.9)
DBP, mm Hg 74.7 (1.3) 75.0 75.7 76.7 0.39 (0.20) 0.05 3.7 (1.9)
Cholesterol, mmol/L 5.83 (0.13) 5.86 5.61 5.76 2.8 (2.0) 0.15 2.8 (1.9)
HDL, mmol/L
Men 1.32 (0.06) 1.29 1.31 1.52 8.2 (8.0) 0.31 3.1 (3.0)
Women 1.60 (0.08) 1.46 1.67 1.68 0.0 (6.7) 0.99 0.0 (2.5)
Triglycerides, mmol/L 1.17 (0.09) 1.47 1.19 0.94 2.9 (2.7) 0.28 2.1 (1.9)
LDL, mmol/L 3.92 (0.13) 3.94 3.70 3.76 3.2 (2.0) 0.12 3.0 (1.9)
Fasting glucose, mmol/L 5.12 (0.16) 5.55 5.22 5.30 0.7 (1.6) 0.67 0.8 (1.9)
FMD, mm 0.24 (0.02) 0.24 0.24 0.19 34 (16) 0.03 4.1 (1.9)
FMD, % 5.67 (0.40) 5.34 5.39 4.29 1.6 (0.6) 0.01 4.7 (1.9)
Abbreviations as in Table 1. Values are mean (SE) when appropriate.
*Regression coefficient shows the change in progression of cIMT associated with a unit change in the RF.
† Coefficient shows the change in progression of cIMT associated with a 1-SD change in the RF. Regression coefficient is shown for gender (women vs men)
and employment grade (lowest vs highest).
‡SEM applies to the means in all 4 quartiles, so it is shown only here.
§Regression and  coefficients for age and gender are mutually adjusted.
Adjusted for age and gender.
Table 3. Association of Baseline FMD (%) With cIMT (mm/y)
Between Phases 5 and 7 and the Effect of Adjustment for
Cardiovascular Disease RFs and FRS
Model (Adjustments)
Regression
Coefficient*
(SE), m P † (SE), m
Model 1 (age and gender) 1.6 (0.6) 0.01 4.7 (1.9)
Model 2 (Individual FRS components‡) 1.5 (0.7) 0.03 4.3 (2.0)
Model 2a (FRS) 1.6 (0.6) 0.01 4.8 (1.9)
Model 2b (FRSwaisttriglycerides) 1.7 (0.6) 0.01 5.0 (1.9)
The relationship between FMD and cIMT per year was of a similar strength
when FMD was expressed as an absolute change (mm) and percentage change
in diameter.
*Regression coefficient shows the change in progression of cIMT associated
with a unit change in the RF.
† Coefficient shows the change in progression of cIMT associated with a
1-SD change in the RF.
‡Model 2 is based on the FRS risk factors (age, gender, systolic blood
pressure, cholesterol, HDL, diabetes mellitus) entered separately.
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impaired endothelial function is associated with more rapid
progression of structural arterial disease in a general, middle-
aged population. This relationship was more robust than, and
independent of, the impact of conventional RFs and the FRS.
Endothelial function testing with FMD may therefore have a
role in identifying those individuals at higher risk of disease
progression and may serve as an appropriate end point for
short- to intermediate-term trials of preclinical intervention.
A dysfunctional endothelium may contribute both to de-
stabilization of established disease and to initiation and
progression of arterial disease. Dynamic vascular changes are
implicated in the activation of atherosclerotic disease, which
leads to plaque destabilization and acute clinical events. The
dysfunctional vascular endothelium has been implicated in
this biology through the production of factors that adversely
affect vascular tone, cellular adhesion, vessel wall inflamma-
tion, and the local thrombotic balance. Measures of endothe-
lium-dependent vasomotor function are strongly linked to
prognosis, even after accounting for the impact of conven-
tional RFs, in higher-risk subjects.13–17,31 Mechanisms impli-
cated in plaque destabilization are likely to be predominantly
responsible because the majority of subjects probably had
significant atheroma burden at the time of endothelial func-
tion testing.
Although previous studies have implicated ED as a key
determinant of disease progression by demonstrating signif-
icant association with the burden of atherosclerotic disease
and its RFs,19,32–36 no previous study has explored prospec-
tively the relationship between ED and evolution of structural
disease. Thus, our study was designed to explore whether
endothelial function testing was able to identify individuals in
the preclinical setting who may be at greater risk of devel-
oping structural atherosclerosis, the substrate for future clin-
ical cardiovascular events.
FMD provides a clinically relevant estimate of local
vascular nitric oxide bioavailability.12 Reduced nitric oxide in
the context of ED results in attenuation of its antimigratory,
antiproliferative, and antiinflammatory functions. In addition,
the dysfunctional endothelium is more permeable to athero-
genic lipoproteins and expresses increased quantities of
proinflammatory cytokines, chemokines, and adhesion mol-
ecules, which enhance leukocyte recruitment to the arterial
wall. ED also results in increased local synthesis and gener-
ation of the vasoactive growth factors endothelin-1 and
angiotensin II. Together, these processes create the ideal
milieu for the initiation and progression of atherosclerotic
disease.
We conducted this study in the Whitehall II study popula-
tion, which is a well-characterized, prospective cohort study
of British civil servants who have been under active
follow-up since 1985.25 We purposely chose participants who
were at low to intermediate risk as determined by their FRS
and baseline cIMT levels because more cardiovascular events
eventually occur in these subjects than in high-risk subjects as
a result of their greater numbers in the population.10 Although
most of the participants in our study were low to intermediate
risk, our findings were similar regardless of whether the
higher-risk individuals receiving statins and antihypertensive
drugs were included in our analysis. More detailed analysis of
vascular risk in low- to intermediate-risk patients is of
particular interest because those at high risk by conventional
assessment methodology would already be considered candi-
dates for aggressive preventive measures.37 Despite the fact
that men had slightly greater cIMT at baseline than women,
the rate of cIMT progression was similar in both sexes. This
was not surprising given that cardiovascular risk is known to
increase markedly in women after menopause, following
relative resistance to clinical atherosclerotic disease during
premenopausal life.19 Our data reflect this, with women
demonstrating a lower “accumulated” cIMT burden than men
by their mid 50s, which incorporates predominantly premeno-
pausal life, but a similar rate of disease progression over
subsequent years.
Smokers were excluded from the study because of the
well-recognized difficulties in accurately quantifying the
level of exposure and the more variable acute influence of
smoking on the results of dynamic vascular endothelial
function testing. We did not assess how circulating biomar-
kers of inflammation relate to vascular dysfunction and
disease progression. These parameters, however, may have
only limited incremental predictive value.38
The careful characterization of the participants and their
RF profiles and the meticulous conduct of the vascular
testing procedures28 are both likely to have contributed to our
ability to characterize the relationships between RFs and
vascular measures and between functional and structural
measures during follow-up, even in our relatively small study
population.
Figure. More rapid progression of carotid structural disease is
seen in those with worse baseline endothelium-dependent vaso-
dilatation. All data are unadjusted. Top, Relationship between
FMD of the brachial artery divided into quartiles (1 indicates the
lowest quartile; 4, highest FMD; annual IMT is expressed
in mm/y). Bottom, Scatterplot demonstrating annual change in
cIMT vs FMD.
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The expected relationships were observed between RFs
and vascular measures at baseline, with the FRS best predict-
ing the presence of structural disease. Although we were
surprised not to see a relationship between FMD and cIMT at
baseline, this finding is most likely explained by the fact that
cIMT, as a structural marker, reflects the impact of lifetime
RF exposure, whereas FMD has more proximal influences.
Juonala et al36 have previously demonstrated a small but
highly significant relationship between FMD and cIMT
(adjusted  cIMT0.0060.002 mm per 1-SD difference
in FMD) in a cross-sectional study of 2000 young
(31.65.0 years of age) individuals. Our findings could be
explained either by the considerable difference in age be-
tween their cohort and ours or by the lower statistical power
of our smaller prospective study to detect this relatively weak
relationship. FMD and cIMT provide complementary infor-
mation on vascular status and should not be compared
directly. FMD is a dynamic measure that reflects the impact
of both acute and chronic influences on endothelial function
and appears to be a more integrated indicator of current
arterial status than individual RF levels. In contrast, cIMT is
a more stable measure of accumulated structural changes in
the arterial wall. Although reflecting both fibromuscular
hyperplasia and intimal and subintimal changes of atheroma,
this measure is reliably associated with both coronary ather-
oma and adverse clinical events.24,39,40
We carefully characterized the key biological determinants
of clinical disease and endothelial function at baseline and
examined their relationship to disease progression. Of these,
FMD was the most closely associated with change in cIMT
over a 6-year period. This finding provides novel evidence
that is consistent with the concept of endothelial function as
a causal determinant of atherogenesis, although our prospec-
tive follow-up data cannot confirm definitively the cause and
effect relationship between the 2 variables. Although some
major RFs were related to cIMT progression, this was less
clear after multivariable analysis. This is likely to reflect the
fact that each individual RF is only partially responsible for
the development of arterial wall changes rather than a direct
measure of overall adverse biological processes involved in
disease development. Similarly, when RF data are presented
according to quartile of cIMT progression (Table 2), waist
circumference and triglyceride levels tended to be lower and
HDL levels tended to be higher in those with most rapid
progression. This is contrary to epidemiological data showing
associations between abdominal obesity with metabolic syn-
drome RF characteristics and cardiovascular disease. LDL
cholesterol levels were no different. Waist circumference,
triglycerides, HDL, and LDL were not consistently associated
with cIMT progression in all analyses, suggesting that type 1
error is the most likely explanation of these modest and
unexpected associations. In contrast, the consistency of the
association between lower FMD and greater cIMT progres-
sion across all of our series of analyses suggests that this
relationship is robust. Notably, receiver-operating character-
istic analysis confirmed the superiority of FMD over conven-
tional risk assessment for the identification of those at an
increased risk of more rapid cIMT progression. An FMD
level of 4.1% was most informative for predicting acceler-
ated cIMT progression. The sensitivity and specificity of this
threshold value to identify rapid progressors were both
65%, and the positive predictive ability was only 35%. This
is in keeping with our previous findings that the negative
predictive value of the test results was most powerful.16 Our
data do not currently support a role for FMD testing in routine
cardiovascular risk assessment, but wider evaluation with
standardized, high-quality testing protocols is warranted.28
Reactive hyperemia was not associated with cIMT progres-
sion and did not influence the relationship between FMD and
cIMT progression, suggesting that it is the endothelial vaso-
motor response to flow that is linked to the progression of
structural arterial abnormalities. Of note, brachial artery
diameter was associated with cIMT progression. In keeping
with the reported relationship between brachial artery diam-
eter and cardiovascular prognosis, remodeling of the brachial
artery may be related to evolution of clinical vascular
disease.13 This issue is somewhat confounded by the fact that
the carotid artery diameter was not associated with cIMT
progression in our study. Further work is required to clarify
these relationships.
We studied preclinical individuals whose arterial wall
biology and structure are more likely to be reversible and in
whom intervention is most likely to have the greatest benefit
on lifetime cardiovascular risk. Although our conclusions
may apply only to low- to intermediate-risk individuals and
further evaluation of this association between FMD and
progression of structural disease in higher risk cohorts is
required, ED has repeatedly been shown to be associated with
a worse cardiovascular prognosis in such patients.11–17,31
Sixty-two participants were unable or unwilling to return
for follow-up vascular assessment at phase 7. Other than
diastolic blood pressure, which was slightly higher in these
participants, all other baseline RFs, including FRS and FMD,
were similar to those in participants who reattended. Al-
though a borderline association was observed between dia-
stolic blood pressure and IMT progression after age and sex
adjustment, it is unlikely that our conclusions would have
been instrumentally altered by the absence of these subjects,
but a small influence cannot be excluded.
RF data that were missing at baseline were imputed from
the participants’ phase 3 data so that no subjects were
excluded from the multivariable analysis. This technique
optimizes the power of the study and avoids the possibility of
any selection bias inherent in selecting only those subjects
with complete data. The proportion of imputed data was low
(6% of the total RF data). These phase 3 data used for the
imputation are our best estimates of the subjects’ current RF
levels, and this method has been used in previous reports
from the Whitehall II study.41 Analyses using the same
models in which the subjects with incomplete RF profiles
were excluded still demonstrated a significant association
between FMD and IMT progression despite the lower statis-
tical power and potential for confounding (data not shown).
We have shown for the first time that endothelial function
as assessed by FMD predicts progression of structural carotid
arterial disease even after taking into account the underlying
RF profile. This result suggests that the combination of cIMT
and FMD provides a measure of both current disease burden
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and likelihood of progression. Our findings complement the
previously reported role of endothelial function testing to
predict risk of acute clinical events in higher-risk sub-
jects.12–17 Given the excellent reproducibility of FMD testing
under carefully controlled experimental conditions,28 FMD
would therefore represent an attractive measure of vascular
status for the assessment of intervention strategies in both the
earlier and later stages of atherosclerotic disease.
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CLINICAL PERSPECTIVE
Atherosclerosis is a multifactorial disease that begins long before its clinical manifestations. A need exists for measures
that improve prediction of disease progression and risk stratification from the “preclinical” phase. Our findings in a group
of middle-aged civil servants demonstrate, for the first time, that a noninvasive measure of endothelial function is
associated with evidence of progression of carotid intima-media thickness over 6 years. This finding adds evidence that
endothelial dysfunction not only is associated with activity of established atherosclerosis and risk of clinical events but also
is likely to be involved in earlier disease development. Carotid intima-media thickness and flow-mediated dilatation
together thus provide a measure of current disease burden and likelihood of progression. Flow-mediated dilatation testing
is an attractive outcome measure for valuation of preventive treatments, as well as for use in patients with established
clinical disease.
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